Home › Funds › ARMISTICE CAPITAL, LLC › NKTR

ARMISTICE CAPITAL, LLC position in NKTR

NEKTAR THERAPEUTICS · Health Care

ARMISTICE CAPITAL, LLC reported holding 700,000 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$42.4M, representing 0.58% of its reported portfolio and ranking #20 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed NKTR holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)700.00K sh
Reported value held$42.38M
Portfolio Weight0.58%
First reportedQ2 2024
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's NKTR position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in NKTR in Q2 2024 at 836,000 shares (US$1.0M). The position peaked in Q2 2026 at 724,000 shares, worth US$50.5M. Across 10 filings, ARMISTICE CAPITAL, LLC increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 700,000 shares valued at US$42.4M — a reduction of -24,000 shares quarter over quarter.. Notable position changes include a 88% trim in Q2 2025 (shares rose 120% over the following quarter), a 116% increase in Q3 2025 (shares fell 26% over the following quarter), a 122% increase in Q4 2025 (shares rose 70% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 836.00K $1.04M New
Q3 2024 1.00M $1.30M Add
Q4 2024 1.02M $952.32K Add
Q1 2025 1.04M $704.48K Add
Q2 2025 124.00K $3.20M Reduce
Q3 2025 268.00K $15.25M Add
Q4 2025 596.00K $25.20M Add
Q1 2026 578.00K $41.59M Reduce
Q2 2026 724.00K $50.54M Add
Q3 2026 700.00K $42.38M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NKTR and 13F data

NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 56 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$166.9M), Vestal Point Capital, LP (US$69.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NKTR

All NKTR fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held NKTR?

ARMISTICE CAPITAL, LLC has disclosed NKTR holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is ARMISTICE CAPITAL, LLC's current position in NKTR?

As of Q3 2026, ARMISTICE CAPITAL, LLC holds 700.00K shares of NKTR (NEKTAR THERAPEUTICS), valued at $42.38M, representing 0.58% of its reported portfolio and ranking #20.

Has ARMISTICE CAPITAL, LLC been buying or selling NKTR?

In the latest 13F filing (Q3 2026), ARMISTICE CAPITAL, LLC reduced its position in NKTR. The position peaked in Q2 2026 at 724.00K shares.

Which other funds hold NKTR?

Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Vestal Point Capital, LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.